Retatrutide Waitlist: Reserve Your Spot for the Next-Generation Weight Loss Medication
TL;DR — The Quick Answer
- Retatrutide is the next-generation triple-hormone weight loss medication from Eli Lilly, expected to receive FDA approval in late 2027 / early 2028
- Phase 2 trials showed 24–28% average weight loss — nearly double semaglutide's results
- Mechanism: Activates GLP-1, GIP, and glucagon receptors simultaneously (vs. one or two with current medications)
- Beyond Stem Cells waitlist is free — no cost, no commitment, just priority access when it launches
- Want help losing weight now? Semaglutide and tirzepatide are available today at our Denver and Las Vegas clinics
- Locations: Littleton, CO (Denver metro) & Las Vegas, NV
The Beyond Stem Cells retatrutide waitlist is a free, no-obligation way to reserve priority access to the next-generation weight loss medication when it receives FDA approval — currently expected in late 2027 or early 2028. Retatrutide is a triple-hormone receptor agonist from Eli Lilly that produced 24–28% average weight loss in Phase 2 trials, significantly exceeding the 12–15% typical of semaglutide and the 15–22% of tirzepatide. By joining the waitlist now, you secure first-call notification and consultation scheduling priority once the medication launches.
If you're already on semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) and getting good results, you might be wondering whether retatrutide is worth waiting for. If you haven't started any weight loss medication yet, you're probably weighing whether to begin treatment now or hold out for the new option. This page answers both questions and lets you reserve your spot in under two minutes.
Join the Retatrutide Waitlist
Free · No obligation · Priority consultation scheduling when retatrutide launches
Why Retatrutide Is Different — The Triple-Hormone Difference
Retatrutide works on three hormone pathways simultaneously, while current medications activate only one or two. That extra pathway is the reason trial results jumped from "good" to genuinely transformative.
| Medication | Hormone Pathways Activated | Avg. Weight Loss | FDA Status |
|---|---|---|---|
| Semaglutide (Ozempic, Wegovy) | GLP-1 only | 12–15% | Approved |
| Tirzepatide (Mounjaro, Zepbound) | GLP-1 + GIP | 15–22% | Approved |
| Retatrutide | GLP-1 + GIP + glucagon | 24–28% | Phase 3 trials (expected approval late 2027/early 2028) |
The first two pathways suppress appetite and improve how your body handles food. The third — the glucagon pathway — is the game-changer. Glucagon receptor activation increases energy expenditure (you burn more calories at rest), aggressively mobilizes stored fat for energy, and appears to preferentially target visceral fat (the dangerous fat around your organs).
"Other GLP-1 medications make you eat less. Retatrutide makes you eat less and burn more of your existing fat stores. You're attacking the problem from both directions at once."
What the Phase 2 Trial Actually Showed
The Phase 2 data released in 2023 surprised even researchers familiar with GLP-1 medications. The 48-week trial enrolled 338 adults with obesity or overweight plus weight-related conditions, with weekly subcutaneous injections at varying doses.
| Dose | Average Weight Loss | What That Means for a 250-lb Person |
|---|---|---|
| Placebo | 2.1% | ~5 lbs |
| 1mg | 8.7% | ~22 lbs |
| 4mg | 17.3% | ~43 lbs |
| 8mg | 22.8% | ~57 lbs |
| 12mg | 24.2% | ~60+ lbs |
Some patients on the 12mg dose lost over 30% of body weight — results that previously required bariatric surgery. Beyond weight, participants saw significant A1C reductions, blood pressure drops averaging 8–10 mmHg systolic, improved cholesterol profiles, and reduced inflammatory markers. The glucagon component also appears to preserve lean muscle mass better than rapid dieting, meaning patients lose more fat and less muscle.
Where Retatrutide Stands in 2026
Retatrutide Development Timeline
Should You Wait for Retatrutide or Start Treatment Now?
The honest answer: most people shouldn't wait. Eighteen months is a long time to delay weight loss in hopes of a "perfect" medication, and current options like semaglutide and tirzepatide already produce excellent results for most patients.
You Should Probably Start a Current Medication Now If…
- You haven't yet tried semaglutide or tirzepatide
- You have weight-related health conditions that need addressing soon (diabetes, sleep apnea, joint problems)
- You're motivated to start losing weight and don't want to wait 18+ months
- Cost is a concern — current medications have established savings programs; retatrutide pricing is unknown
- You want to see real progress on the scale within 3–6 months
The Retatrutide Waitlist Makes Most Sense If…
- You've already plateaued on semaglutide or tirzepatide and want a more aggressive option
- You have significant weight to lose (50+ lbs / BMI 35+) and want maximum medication effect
- You've tried current GLP-1s and found the results good but not sufficient
- You're stable, in no urgent health hurry, and prefer to start with the most powerful tool available
You don't have to choose. Many patients join the waitlist and start a current medication immediately, then transition to retatrutide when it becomes available if appropriate.
How Retatrutide Treatment Will Likely Work
Based on trial data and experience with similar medications, retatrutide treatment will likely follow this pattern when it launches:
Expected Retatrutide Protocol
- Weeks 1–4: Low starting dose (~2mg weekly). Allows your body to adapt and minimizes early side effects.
- Weeks 5–8: First increase (~4mg weekly). Gradual titration continues.
- Weeks 9–12: Second increase (~8mg weekly). Reaching meaningful therapeutic dose.
- Weeks 13+: Target dose (~12mg weekly). The dose where Phase 2 data showed 24–28% weight loss.
- Months 6–12: Continued progress. Most patients reach 15–28% total weight loss in this window.
- Months 12–18+: Maintenance phase. Some patients continue at maintenance doses long-term to prevent regain.
Side effects mirror other GLP-1 medications — nausea, reduced appetite, digestive changes, fatigue during dose escalation. About 10–15% of trial participants discontinued due to side effects, comparable to semaglutide and tirzepatide. Most effects are mild to moderate and decrease as your body adapts.
Pricing & Insurance Outlook
What We Know — and Don't Know — About Retatrutide Pricing
- Industry analysts project launch pricing of $1,200–$1,500 per month (slightly above current Mounjaro/Zepbound rates)
- Insurance coverage at launch will likely be limited; most patients will pay cash initially
- Manufacturer savings programs typically emerge within 6–12 months of launch
- Competing triple-agonist medications from other companies are 1–2 years behind in development — competition should eventually drive prices down
- Beyond Stem Cells will help waitlist members navigate insurance, savings programs, and financing when retatrutide launches
Why Choose Beyond Stem Cells for Retatrutide
What Sets Our Retatrutide Program Apart
- Early-adoption preparation. We're studying trial data and developing protocols now, so we're ready to prescribe safely from day one of FDA approval — not learning on the fly.
- Thousands of GLP-1 prescriptions of experience. We've prescribed extensively with semaglutide and tirzepatide. The mechanisms overlap, so that experience translates directly to retatrutide.
- Comprehensive medical supervision. Initial evaluation, personalized dosing, proactive side effect management, regular monitoring — not a prescription mill.
- Integration with complementary treatments. We combine weight loss medications with peptide therapy for muscle preservation, IV therapy for nutrition support, and hormone optimization when needed.
- Transparent pricing and insurance navigation. We tell you exactly what treatment costs and help with prior authorizations, savings programs, and financing.
- Waitlist priority. Members get first-call scheduling when retatrutide becomes available.
Service Areas — Denver Metro & Las Vegas
The retatrutide waitlist is open to patients across our Denver metro and Las Vegas service areas:
Don't Wait to Lose Weight — Reserve Your Retatrutide Spot Today
Joining the waitlist takes under two minutes and creates no obligation. If you want help with weight loss right now, we have current options ready to start this week. Either way, we'd love to talk.
Call to Discuss Your Options 📞 (833) 720-7836Frequently Asked Questions
What is retatrutide?
Retatrutide is a next-generation triple-hormone receptor agonist developed by Eli Lilly that activates GLP-1, GIP, and glucagon pathways simultaneously. Phase 2 clinical trials produced 24–28% average weight loss at the highest dose, exceeding semaglutide (12–15%) and tirzepatide (15–22%). It is currently in Phase 3 trials and not yet FDA approved.
When will retatrutide be available?
Based on Eli Lilly's trial timeline and public statements, retatrutide is expected to receive FDA approval in late 2027 or early 2028, with prescriptions becoming available shortly after approval. Beyond Stem Cells is preparing protocols now and will offer retatrutide as soon as it is legally available.
How is retatrutide different from Ozempic and Mounjaro?
Semaglutide (Ozempic, Wegovy) activates one hormone pathway (GLP-1). Tirzepatide (Mounjaro, Zepbound) activates two (GLP-1 and GIP). Retatrutide activates all three (GLP-1, GIP, and glucagon). The glucagon pathway increases energy expenditure and aggressively mobilizes stored fat — producing significantly greater weight loss in clinical trials.
Does the retatrutide waitlist cost anything?
No. Joining the Beyond Stem Cells retatrutide waitlist is free and creates no obligation. You will be contacted when the medication becomes FDA-approved and we are ready to prescribe. You decide at that point whether to proceed with treatment.
Should I wait for retatrutide or start a weight loss medication now?
For most patients, starting current options like semaglutide or tirzepatide makes more sense than waiting 18+ months for retatrutide. You can transition to retatrutide if appropriate when it launches. If you have already plateaued on current medications, joining the waitlist while continuing current treatment is reasonable. A consultation can help determine the best path.
Who is a good candidate for retatrutide when it launches?
Strong candidates have BMI 30+ or significant weight to lose (50+ pounds), have tried diet and exercise without sustained success, and may have weight-related conditions like diabetes, hypertension, fatty liver, or sleep apnea. People who plateaued on semaglutide or tirzepatide and need more aggressive results are also strong candidates.
How much will retatrutide cost?
Pricing has not been finalized. Industry analysts project retatrutide will launch in the $1,200–$1,500 monthly range, slightly above current Mounjaro/Zepbound pricing. Manufacturer savings programs and insurance coverage will likely emerge to improve affordability over time.
Will Beyond Stem Cells participate in retatrutide clinical trials?
Beyond Stem Cells is not a clinical trial site for retatrutide. Phase 3 trials are conducted at Eli Lilly's selected research centers and are now closed to new enrollment. Our waitlist is for patients who want priority access to retatrutide once it receives FDA approval and is available by prescription.
Where are Beyond Stem Cells clinics located?
We have two clinics: 5912 S Cody St., Suite 201 in Littleton, Colorado (serving the Denver metro) and 9830 W. Tropicana Ave. Suite 165 in Las Vegas, Nevada. Both are open Monday through Saturday.